What is Avalo Therapeutics's EV / sales?

Avalo Therapeutics (AVTX) reported EV / sales of -127.1× in Q4 2024.

How has Avalo Therapeutics's EV / sales changed year-over-year?

Avalo Therapeutics's EV / sales decreased by 14908.8% year-over-year, from 0.9× to -127.1×.

What is the long-term trend for Avalo Therapeutics's EV / sales?

Over 4 years (2020 to 2024), Avalo Therapeutics's EV / sales has grown at a 38.3% compound annual growth rate (CAGR), from 34.7× to -127.1×.

What does EV / sales mean?

Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.

Avalo Therapeutics AVTX EV / sales

EV / sales at other companies

Eli LillyLLY

11.9×-4.0×

AbbVieABBV

7.5×+1.0×

XencorXNCR

10.7×+3.4×

AnaptysBio, Inc.ANAB

5.8×+1.4×

AbCellera Biologics Inc.ABCL

13.8×-9.9×

Absci CorporationABSI

246.9×+193×

Other financials

Income statement

See full

Revenue$59.0K-69.3%

Gross profit$963.0K+8,855%

Operating income-$20.9M-42.5%

Net income-$19.6M-49.3%

EPS (diluted)-$0.98+21.6%

Balance sheet

See full

Cash & equivalents$25.3M-79.8%

Total debt$328.0K-59.1%

Total equity$68.3M-44.3%

Total assets$99.9M-27.9%

Cash flow

See full

Operating cash flow-$17.7M-87.1%

CapEx-—

Free cash flow-$15.0M-444%

Valuation

See full

Market cap$954.59M+1,783%

Enterprise value$929.6M-1,342%

P/S1,909.2×+1,868×

Profitability

See full

Gross margin182%+176pp

Operating margin-15,536.1%-17,275pp

Net margin-7,965.8%-10,750pp

FCF margin-11,123.8%-13,374pp

Returns & leverage

See full

Return on equity-88.8%—

Debt / equity0×0.0×

Current ratio7.7×-14.9×

Where this comes from

Calculated from Avalo Therapeutics’s reported figures.

enterprise value/total revenue=-127.1×

Based on the most recent quarter.

The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Avalo Therapeutics's ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Avalo Therapeutics's EV / sales?: Avalo Therapeutics (AVTX) reported EV / sales of -127.1× in Q4 2024.
How has Avalo Therapeutics's EV / sales changed year-over-year?: Avalo Therapeutics's EV / sales decreased by 14908.8% year-over-year, from 0.9× to -127.1×.
What is the long-term trend for Avalo Therapeutics's EV / sales?: Over 4 years (2020 to 2024), Avalo Therapeutics's EV / sales has grown at a 38.3% compound annual growth rate (CAGR), from 34.7× to -127.1×.
What does EV / sales mean?: Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.